A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as data became available from Phase 3 trials of perioperative regimens combining chemotherapy with immunotherapy showing improved efficacy outcomes versus chemotherapy alone.

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Atezolizumab
DRUG: Tiragolumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Gemcitabine
DRUG: Paclitaxel

Sponsor

Hoffmann-La Roche